Osiris Therapeutics now holds the orphan-drug designation in Europe for its stem cell treatment Prochymal for acute graft-versus-host disease in bone marrow transplant patients. The move will make it easier for Osiris to secure a partnership or sale.
Osiris gets European orphan-drug title for Prochymal
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||